FGF-18 alleviates memory impairments and neuropathological changes in a rat model of Alzheimer's disease

Basit Öğe Kaydı
dc.authorid0000-0002-2778-8059tr
dc.contributor.authorÇetindağ Çiltaş, Arzuhan
dc.contributor.authorKarabulut Sebahattin
dc.contributor.authorŞahin Bilal
dc.contributor.authorFiliz, Ahmet Kemal
dc.contributor.authorYulak Fatih
dc.contributor.authorÖzkaraca Mustafa
dc.contributor.authorKarataş, Özhan
dc.contributor.authorÇetin, Ali
dc.date.accessioned2024-03-07T05:19:16Z
dc.date.available2024-03-07T05:19:16Z
dc.date.issued22.07.2023tr
dc.departmentVeteriner Fakültesitr
dc.description.abstractAlzheimer’s disease (AD) is a multifactorial pathology marked by amyloid beta (Aβ) accumulation, tau hyperphosphorylation, and progressive cognitive decline. Previous studies show that fibroblast growth factor 18 (FGF18) exerts a neuroprotective effect in experimental models of neurodegeneration; however, how it affects AD pathology remains unknown. This study aimed to ascertain the impact of FGF18 on the behavioral and neuropathological changes in the rat model of sporadic AD induced by intracerebroventricular (ICV) injection of streptozotocin (STZ). The rats were treated with FGF18 (0.94 and 1.88 pmol, ICV) on the 15th day after STZ injection. Their cognitive function was assessed in the Morris water maze and passive avoidance tests for 5 days from the 16th to the 21st days. Aβ levels and histological signs of neurotoxicity were detected using the enzymelinked immunosorbent assay (ELISA) assay and histopathological analysis of the brain, respectively. FGF18 mildly ameliorated the STZ-induced cognitive impairment; the Aβ accumulation was reduced; and the neuronal damage including pyknosis and apoptosis was alleviated in the rat brain. This study highlights the promising therapeutic potential for FGF18 in managing AD.tr
dc.identifier.doi10.1016/j.npep.2023.102367en_US
dc.identifier.pmid37506425en_US
dc.identifier.scopus2-s2.0-85165658037en_US
dc.identifier.scopusqualityN/A
dc.identifier.urihttps://hdl.handle.net/20.500.12418/14807
dc.identifier.wosWOS:001052597500001en_US
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.relation.publicationcategoryUluslararası Hakemli Dergide Makale - Kurum Öğretim Elemanıtr
dc.rightsinfo:eu-repo/semantics/openAccesstr
dc.subjectAlzheimer’s disease, Streptozotocin, FGF18, Rattr
dc.titleFGF-18 alleviates memory impairments and neuropathological changes in a rat model of Alzheimer's diseaseen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
1-s2.0-S0143417923000483-main (1).pdf
Boyut:
7.12 MB
Biçim:
Adobe Portable Document Format
Açıklama:
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Klinik Öncesi Bilimleri Bölümü Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu